CRL Charles River Laboratories International Inc

Price (delayed)

$186.6

Market cap

$8.99B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.7

Enterprise value

$11.85B

?
Relative Growth: Rel. Growth: 12
Relative Strength: Rel. Strength: 61
Relative Valuation: Rel. Valuation: 23
Relative Profitability: Rel. Profitability: 22

Charles River Laboratories, Inc., is an American corporation specializing in a variety of preclinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted ...

Highlights
The net income has declined by 28% since the previous quarter
The EPS fell by 27% QoQ

Key stats

What are the main financial stats of CRL

CRL stock price

How has the Charles River Laboratories International stock price performed over time
Intraday
2.78%
1 week
0.98%
1 month
16.41%
1 year
26.61%
YTD
-6.46%
QTD
8.17%

Financial performance

How have Charles River Laboratories International's revenue and profit performed over time
Revenue
$4.03B
Gross profit
$1.3B
Operating income
$70.39M
Net income
-$184.65M
Gross margin
32.3%
Net margin
-4.6%
The operating margin has soared by 183% QoQ but it has shrunk by 61% YoY
CRL's operating income has soared by 180% QoQ but it has shrunk by 60% YoY
The net income has declined by 28% since the previous quarter
Charles River Laboratories International's net margin has decreased by 28% QoQ

Price vs fundamentals

How does CRL's price correlate with its fundamentals

Growth

What is Charles River Laboratories International's growth rate over time

Valuation

What is Charles River Laboratories International stock price valuation
P/E
N/A
P/B
3.12
P/S
2.27
EV/EBIT
N/A
EV/EBITDA
41.05
EV/Sales
2.94
The EPS fell by 27% QoQ
The price to book (P/B) is 25% higher than the last 4 quarters average of 2.5 but 22% lower than the 5-year quarterly average of 4.0
The equity has declined by 8% year-on-year and by 7% since the previous quarter
The P/S is 27% lower than the 5-year quarterly average of 3.1 but 14% higher than the last 4 quarters average of 2.0

Efficiency

How efficient is Charles River Laboratories International business performance
The company's return on invested capital has shrunk by 142% YoY
The ROS has shrunk by 141% YoY
The company's return on assets fell by 32% QoQ
The ROE has contracted by 30% from the previous quarter

Dividends

What is CRL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRL.

Financial health

How did Charles River Laboratories International financials performed over time
The company's total assets is 63% higher than its total liabilities
The total liabilities rose by 21% QoQ and by 9% YoY
The quick ratio has declined by 13% year-on-year
Charles River Laboratories International's debt is 3.9% higher than its equity
Charles River Laboratories International's debt to equity has increased by 28% from the previous quarter and by 12% YoY
Charles River Laboratories International's debt has increased by 19% QoQ and by 2.4% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.